참고문헌
- Al Hajj M (2007). Cancer stem cells and oncology therapeutics. Curr Opin Oncol, 19, 61-4.
- Arciero CA (2010). Ki-67 proliferation index and gastric cancer: Answers or More Questions. J Surg Onco, 102, 199-200. https://doi.org/10.1002/jso.21626
- Baba T, Convery P, Matsumura N, et al (2009). Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene, 28, 209-18. https://doi.org/10.1038/onc.2008.374
- Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005). Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res, 65, 10946-51. https://doi.org/10.1158/0008-5472.CAN-05-2018
- Ferlay J, Soerjomataram I, Ervik M, et al (2013). GLOBOCAN 2012 v1.0, Cancer incidence and Mortality worldwide: IARC Cancer Base No.11 (Internet). Web address: http://globocan.iarc.fr
- Hashimato K, Aoyagi K, Isobe T, Kouhuji K, Shirouzu K (2014). Expression of CD133 in the cytoplasm is associated with cancer progression and poor prognosis in gastric cancer. Gastric Cancer, 17, 97-106. https://doi.org/10.1007/s10120-013-0255-9
- He WL, Li YH, Yang DJ, et al (2013). Combined evaluation of centromere protein H and Ki-67 as prognostic biomarker for patient with gastric carcinoma. Eur J Surg Oncol, 39, 141-9. https://doi.org/10.1016/j.ejso.2012.08.023
- Horst D, Kriegl L, Engel J, Kirchner T, Jung A (2008). CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer, 99, 1285-9. https://doi.org/10.1038/sj.bjc.6604664
- Ishigami S, Uenu S, Arigami T, et al (2010). Prognostic impact of CD133 expression in gastric carcinoma. Anticancer Res, 30, 2453-7.
- Jiang Y, He Y, Li H et al (2012). Expressions of putative cancer stem cell markers ABCB1, ABCG2, and CD133 are correlated with the degree of differentiation of gastric cancer. Gastric Cancer, 15, 440-50. https://doi.org/10.1007/s10120-012-0140-y
- Jordan CT, Guzman ML, Noble M (2006). Cancer stem cells. N Engl J Med, 355, 1253-61. https://doi.org/10.1056/NEJMra061808
- Lazar D, Taban S, Sporea I et al (2010). Ki-67 expression in gastric cancer. Results from a prospective study with longterm follow-up. Rom J Morphol Embryol, 51, 655-61.
- Lee HE, Kim MA, Lee BL, Kim WH (2010). Low Ki-67 proliferation index is an indicator of poor prognosis in gastric cancer. J Surg Oncol, 102, 201-6. https://doi.org/10.1002/jso.21583
- Lee HH, Seo KJ, An CH, Kim JS, Jeon HM (2012). CD133 expression is correlated with chemoresistance and early recurrence of gastric cancer. J Surg Oncol, 106, 999-1004. https://doi.org/10.1002/jso.23178
- Li C, Heidt DG, Dalerba P, et al (2007). Identification of pancreatic cancer stem cells. Cancer Res, 67, 1030-7. https://doi.org/10.1158/0008-5472.CAN-06-2030
- Maeda S, Shinchi H, Kurahara H, et al (2008). CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br J Cancer, 98, 1389-97. https://doi.org/10.1038/sj.bjc.6604307
- Neuzil J, Stantic M, Zobalova R, et al (2007). Tumour-initiating cellsvs. cancer 'stem' cells and CD133: what' s the name? Biochem Biophys Res Commun, 355, 855-9. https://doi.org/10.1016/j.bbrc.2007.01.159
- O' Brien CA, Kreso A, Dick JE (2009). Cancer stem cells in solid tumors: An Overview. Seminars Rad Oncology, 19, 71-7.
- Reya T, Morrison SJ, Clarke MF, Weissman IL (2001). Stem cells, cancer, and cancer stem cells. Nature, 414, 105-11. https://doi.org/10.1038/35102167
- Ross W, Hall PA (1995). Ki67: from antibody to molecule to understanding? J Clin Pathol: Mol Pathol, 48, 113-7. https://doi.org/10.1136/mp.48.3.M113
- Sanaat Z, Halimi M, Ghojezadeh M, et al (2013). Immunohistochemical analysis of p53, Ki-67, CD44, HER-2/neu expression patterns in gastric cancer, and their associatin with one year survival in North-West of Iran. Int J Hematol Oncol Stem Cell Res, 7, 15-20.
- Satpute PS, Hazarey V, Ahmed R, Yadav L (2013). Cancer stem cells in head and neck squmous cell carcinoma: a review. Asian Pac J Cancer Prev, 14, 5579-87. https://doi.org/10.7314/APJCP.2013.14.10.5579
- Scholzen T, Gerdes J (2000). The Ki-67 protein: From the known and the unknown. J Cell Physiol, 182, 311-22. https://doi.org/10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9
- Setoguchi T, Taga T, Kondo T (2004). Cancer stem cells persist in many cancer cell lines. Cell Cycle, 3, 414-5. https://doi.org/10.4161/cc.3.4.799
- Smith LM, Nestevora A, Ryan MC, et al (2008). CD133/prominin-1 is a potential therapeutic target for antibodydrug conjugates in hepatocellular and gastric cancers. Br J Cancer, 99, 100-9. https://doi.org/10.1038/sj.bjc.6604437
- Tabarestani S, Ghafouri-Fard S (2012). Cancer stem cells and response to therapy. Asian Pac J Cancer Prev, 13, 5947-54. https://doi.org/10.7314/APJCP.2012.13.12.5947
- Tang C, Ang BT, Pervaiz S (2007). Cancer stem cell: target for anti-cancer therapy. FASEB J, 21, 3777-85. https://doi.org/10.1096/fj.07-8560rev
- Turkish Public Health Organization (2009). Web address: http://kanser.gov.tr/daire-faaliyetleri/kanser-istatistikleri.html
- Yang X, Wang F, Chen C, et al (2011). High Ki-67 expression is a poor prognostic indicator of 5-year survival in patients with invasive breast cancer. Asian Pac J Cancer Prev, 12, 3101-4.
- Yao Q, Sun J, Ma H, et al (2014) Monitoring microRNAs using a molecular beacon in CD133+/CD338+ human lung adenocarcinoma-initiating A549 cells. Asian Pac J Cancer Prev, 15, 161-6. https://doi.org/10.7314/APJCP.2014.15.1.161
- Yu JW, Zhang P, Wu JG, et al (2010). Expressions and clinical significances of CD133 protein and CD133 mRNA in primary lesion of gastric adenocarcinoma. J of Experimental and Clinic Cancer Resarch, 7, 29-141.
- Yu JW, Wang SL, Wu JG, et al (2014). Study on the biological characteristics of CD133 (+) cells interfered by RNA interference in gastric cancer. ISRN Gastroenterol, 19, 329519.
- Weidner N, Moore DH 2nd, Vartanian R (1994). Correlation of Ki-67 antijen expression with mitotic Figure index and tumor grade in breast carcinomas using the novel 'paraffin' reactive MIBI antibody. Hum Pathol, 25, 337-42. https://doi.org/10.1016/0046-8177(94)90140-6
- Wen L, Chen X,Yang K, et al (2013). Prognostic value of cancer stem cell marker CD133 expression in gastric cancer: A systematic Review. PLoS ONE, 8, 59154. https://doi.org/10.1371/journal.pone.0059154
- Zhao P, Li Y, Lu Y (2010). Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma. BMC Cancer, 10, 218. https://doi.org/10.1186/1471-2407-10-218
- Zhao P, Lu Y, Jiang X, Li X (2011). Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma. Cancer Sci, 102, 1107-11. https://doi.org/10.1111/j.1349-7006.2011.01894.x
- Zeppernick F, Ahmadi R, Campos B, et al (2008). Stem cell marker CD133 affects clinical outcome in gloma patients. Clin Cancer Res, 14, 123-9. https://doi.org/10.1158/1078-0432.CCR-07-0932
피인용 문헌
- Clinicopathological Significance of CD133 and ALDH1 Cancer Stem Cell Marker Expression in Invasive Ductal Breast Carcinoma vol.16, pp.17, 2015, https://doi.org/10.7314/APJCP.2015.16.17.7491
- Ginsenoside-Rh2 Inhibits Proliferation and Induces Apoptosis of Human Gastric Cancer SGC-7901 Side Population Cells vol.17, pp.4, 2016, https://doi.org/10.7314/APJCP.2016.17.4.1817
- Clinicopathological and prognostic significance of cancer stem cell markers CD44 and CD133 in patients with gastric cancer vol.95, pp.42, 2016, https://doi.org/10.1097/MD.0000000000005163
- Dual Energy Spectral CT Imaging in the assessment of Gastric Cancer and cell proliferation: A Preliminary Study vol.8, pp.1, 2018, https://doi.org/10.1038/s41598-018-35712-w
- Incorporation of p-53 mutation status and Ki-67 proliferating index in classifying Her2-neu positive gastric adenocarcinoma vol.13, pp.1, 2018, https://doi.org/10.1080/19932820.2018.1466573